173 related articles for article (PubMed ID: 27615706)
21. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
[TBL] [Abstract][Full Text] [Related]
22. Aggressive Pituitary Adenomas: The Dark Side of the Moon.
Priola SM; Esposito F; Cannavò S; Conti A; Abbritti RV; Barresi V; Baldari S; Ferraù F; Germanò A; Tomasello F; Angileri FF
World Neurosurg; 2017 Jan; 97():140-155. PubMed ID: 27713064
[TBL] [Abstract][Full Text] [Related]
23. Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: a case report of early identification and management.
Zhong C; Yin S; Zhou P; Jiang S
Turk Neurosurg; 2014; 24(6):963-6. PubMed ID: 25448217
[TBL] [Abstract][Full Text] [Related]
24. Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide.
Batisse M; Raverot G; Maqdasy S; Durando X; Sturm N; Montoriol PF; Kemeny JL; Chazal J; Trouillas J; Tauveron I
Cancer Invest; 2013 Mar; 31(3):190-6. PubMed ID: 23477586
[TBL] [Abstract][Full Text] [Related]
25. Aggressive pituitary adenomas--diagnosis and emerging treatments.
Di Ieva A; Rotondo F; Syro LV; Cusimano MD; Kovacs K
Nat Rev Endocrinol; 2014 Jul; 10(7):423-35. PubMed ID: 24821329
[TBL] [Abstract][Full Text] [Related]
26. Use of temozolomide in aggressive pituitary tumors: case report.
Mohammed S; Kovacs K; Mason W; Smyth H; Cusimano MD
Neurosurgery; 2009 Apr; 64(4):E773-4; discussion E774. PubMed ID: 19349807
[TBL] [Abstract][Full Text] [Related]
27. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.
Raverot G; Jouanneau E; Trouillas J
Eur J Endocrinol; 2014 Apr; 170(4):R121-32. PubMed ID: 24431196
[TBL] [Abstract][Full Text] [Related]
28. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
[TBL] [Abstract][Full Text] [Related]
29. Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
Thearle MS; Freda PU; Bruce JN; Isaacson SR; Lee Y; Fine RL
Pituitary; 2011 Dec; 14(4):418-24. PubMed ID: 19960369
[TBL] [Abstract][Full Text] [Related]
30. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
[TBL] [Abstract][Full Text] [Related]
31. Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.
Ghazi AA; Rotondo F; Kovacs K; Amirbaigloo A; Syro LV; Fathalla H; Di Ieva A; Cusimano MD
Endocr Pathol; 2015 May; 26(2):135-9. PubMed ID: 25716461
[TBL] [Abstract][Full Text] [Related]
32. Von Hippel-Lindau disease and aggressive GH-PRL pituitary adenoma in a young boy.
Tudorancea A; François P; Trouillas J; Cottier JP; Girard JJ; Jan M; Gilbert-Dussardier B; Richard S; Lecomte P
Ann Endocrinol (Paris); 2012 Feb; 73(1):37-42. PubMed ID: 22265326
[TBL] [Abstract][Full Text] [Related]
33. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
[TBL] [Abstract][Full Text] [Related]
34. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Lenders N; McCormack A
Pituitary; 2018 Apr; 21(2):217-229. PubMed ID: 29299820
[TBL] [Abstract][Full Text] [Related]
35. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B
Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
[TBL] [Abstract][Full Text] [Related]
36. SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases.
Bode H; Seiz M; Lammert A; Brockmann MA; Back W; Hammes HP; Thomé C
Exp Clin Endocrinol Diabetes; 2010 Nov; 118(10):760-3. PubMed ID: 20496311
[TBL] [Abstract][Full Text] [Related]
37. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
Ceccato F; Lombardi G; Manara R; Emanuelli E; Denaro L; Milanese L; Gardiman MP; Bertorelle R; Scanarini M; D'Avella D; Occhi G; Boscaro M; Zagonel V; Scaroni C
J Neurooncol; 2015 Mar; 122(1):189-96. PubMed ID: 25555563
[TBL] [Abstract][Full Text] [Related]
38. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
Wahl M; Chang SM; Phillips JJ; Molinaro AM; Costello JF; Mazor T; Alexandrescu S; Lupo JM; Nelson SJ; Berger M; Prados M; Taylor JW; Butowski N; Clarke JL; Haas-Kogan D
Cancer; 2017 Dec; 123(23):4631-4639. PubMed ID: 28759109
[TBL] [Abstract][Full Text] [Related]
39. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
Zacharia BE; Gulati AP; Bruce JN; Carminucci AS; Wardlaw SL; Siegelin M; Remotti H; Lignelli A; Fine RL
Neurosurgery; 2014 Apr; 74(4):E447-55; discussion E455. PubMed ID: 24226425
[TBL] [Abstract][Full Text] [Related]
40. Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
Philippon M; Morange I; Barrie M; Barlier A; Taieb D; Dufour H; Conte-Devolx B; Brue T; Castinetti F
Ann Endocrinol (Paris); 2012 Jun; 73(3):225-9. PubMed ID: 22520146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
